Overview

Phase 2 of HU-045 in Glabellar Lines

Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Phase:
Phase 2
Details
Lead Sponsor:
Huons Co., Ltd.
Treatments:
Botulinum Toxins, Type A
incobotulinumtoxinA